Dual Antiplatelet Therapy Role in Acute Ischemic Stroke

Stroke is the second greatest cause of mortality and one of the top causes of long-term disability. The fatality rate and age-adjusted prevalence of stroke have decreased globally over the past quarter-century. However, the absolute number of stroke cases has climbed, as populations have grown older. Initiating antiplatelet medications early in patients with acute ischemic stroke (AIS) is essential for preventing stroke recurrence. Aspirin, clopidogrel, and dipyridamole are the most commonly used antiplatelet medications worldwide. Combining antiplatelet drugs is associated with an increased risk of bleeding when used for long-term prophylaxis. The use of Dual antiplatelet treatment (DAPT) for a shorter duration is associated with a lower risk than long-term usage. The best period of treatment for transient ischemic attack (TIA) and mild ischemic stroke appears to be between 21 and 30 days.